CELCUITY INC.
CELCLoading price...
Overview
Previous Close122.96
Open95.00
Ask157.49
Bid68.40
Day's Range91.63 - 99.83
52 Week Range11.09 - 151.02
PE Ratio(TTM)--
Market Cap4.59B
Volume4.05M
Avg. Volume938.89k
12 Months Earnings-192.89M
12 Months Revenue0.00
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 186.57M | 172.19M | 113.27M | 66.23M | 39.39M |
| Profit after Tax (Net Income) | -192.89M | -177.04M | -111.78M | -63.78M | -40.37M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Minneapolis, United States
Website: https://www.celcuity.com
Co-Founder, Chairman & CEO: Mr. Brian F. Sullivan
Employees: 155
About Company:
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.